Compare Stocks → top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (From Traders Agency) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ERYPNASDAQ:EVAXNASDAQ:GNFTNASDAQ:JSPRNASDAQ:MIRO Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeERYPERYTECH Pharma$3.10$4.66$0.30▼$1.47$105.77M2.6993,510 shsN/AEVAXEvaxion Biotech A/S$4.13$3.56$2.82▼$18.50$21.56M-0.02538,100 shs3,060 shsGNFTGenfit$3.45$3.59$2.89▼$4.75$171.66M1.084,408 shs3,539 shsJSPRJasper Therapeutics$21.55-2.2%$24.82$4.00▼$31.01$324.54M2.22117,630 shs4,893 shsMIROMiromatrix Medical$3.39$3.38$0.91▼$4.35$92.95M0.0180,095 shsN/AThese 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceERYPERYTECH Pharma0.00%0.00%0.00%-34.04%+254.29%EVAXEvaxion Biotech A/S-0.24%+0.49%+33.23%-56.11%-68.47%GNFTGenfit+0.44%-0.43%-5.36%-11.21%-7.89%JSPRJasper Therapeutics-0.36%-7.51%-20.47%+95.65%+82.07%MIROMiromatrix Medical0.00%0.00%0.00%0.00%+160.77%This Apple-like Innovator is Revolutionizing Healthcare (Ad)AI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.Click here to learn more about the booming eHealth industryMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationERYPERYTECH PharmaN/AN/AN/AN/AN/AN/AN/AN/AEVAXEvaxion Biotech A/S1.6061 of 5 stars3.53.00.00.00.41.70.6GNFTGenfit0.8098 of 5 stars3.53.00.00.00.60.00.0JSPRJasper Therapeutics2.9597 of 5 stars3.53.00.00.02.73.30.6MIROMiromatrix MedicalN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceERYPERYTECH PharmaN/AN/AN/AN/AEVAXEvaxion Biotech A/S3.00Buy$11.00166.34% UpsideGNFTGenfit3.00Buy$11.00219.30% UpsideJSPRJasper Therapeutics3.00Buy$64.17197.76% UpsideMIROMiromatrix MedicalN/AN/A$3.00-11.50% DownsideCurrent Analyst RatingsLatest ERYP, GNFT, JSPR, EVAX, and MIRO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/5/2024GNFTGenfitHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$11.004/3/2024EVAXEvaxion Biotech A/SHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$14.004/3/2024JSPRJasper TherapeuticsEvercore ISISubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$65.004/2/2024EVAXEvaxion Biotech A/SLADENBURG THALM/SH SHSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$8.003/28/2024JSPRJasper TherapeuticsRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$70.003/20/2024EVAXEvaxion Biotech A/SHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$14.003/18/2024JSPRJasper TherapeuticsTD CowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform3/7/2024JSPRJasper TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$80.002/12/2024EVAXEvaxion Biotech A/SHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$14.00(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookERYPERYTECH Pharma$32.66M3.24N/AN/A$0.80 per share3.88EVAXEvaxion Biotech A/S$70K307.98N/AN/A($1.17) per share-3.53GNFTGenfit$41.31M4.16N/AN/A$1.48 per share2.33JSPRJasper TherapeuticsN/AN/AN/AN/A$7.03 per shareN/AMIROMiromatrix Medical$958.03K97.02N/AN/A$1.25 per share2.71Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateERYPERYTECH Pharma-$240KN/A0.00∞N/AN/AN/AN/AN/AEVAXEvaxion Biotech A/S-$22.12M-$6.76N/A31.77N/AN/A-451.63%-149.27%5/29/2024 (Estimated)GNFTGenfit-$31.27MN/A0.00N/AN/AN/AN/AN/A7/4/2024 (Estimated)JSPRJasper Therapeutics-$64.46M-$6.20N/AN/AN/AN/A-63.21%-55.07%5/10/2024 (Estimated)MIROMiromatrix Medical-$29.96M-$1.14N/A∞N/A-2,861.17%-120.49%-90.70%N/ALatest ERYP, GNFT, JSPR, EVAX, and MIRO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/27/2024Q4 2023EVAXEvaxion Biotech A/SN/A-$0.16-$0.16-$0.16N/A$0.07 million3/4/2024Q4 2023JSPRJasper Therapeutics-$1.65-$1.50+$0.15-$1.50N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthERYPERYTECH PharmaN/AN/AN/AN/AN/AEVAXEvaxion Biotech A/SN/AN/AN/AN/AN/AGNFTGenfitN/AN/AN/AN/AN/AJSPRJasper TherapeuticsN/AN/AN/AN/AN/AMIROMiromatrix MedicalN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioERYPERYTECH Pharma0.323.653.65EVAXEvaxion Biotech A/SN/A1.181.18GNFTGenfit0.922.942.94JSPRJasper TherapeuticsN/A7.197.19MIROMiromatrix Medical0.023.463.46OwnershipInstitutional OwnershipCompanyInstitutional OwnershipERYPERYTECH Pharma1.09%EVAXEvaxion Biotech A/S11.04%GNFTGenfit2.24%JSPRJasper Therapeutics79.85%MIROMiromatrix Medical29.38%Insider OwnershipCompanyInsider OwnershipERYPERYTECH Pharma1.94%EVAXEvaxion Biotech A/S41.64%GNFTGenfit4.20%JSPRJasper Therapeutics3.90%MIROMiromatrix Medical5.20%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableERYPERYTECH Pharma4934.12 million33.46 millionNot OptionableEVAXEvaxion Biotech A/S635.22 million3.04 millionOptionableGNFTGenfit15949.83 million47.74 millionNot OptionableJSPRJasper Therapeutics4515.06 million14.48 millionOptionableMIROMiromatrix Medical7627.42 million25.99 millionOptionableERYP, GNFT, JSPR, EVAX, and MIRO HeadlinesSourceHeadlineWalter Reed Army Medical Centermilitary.com - March 2 at 8:07 PMQ4 2023 United Therapeutics Corp Earnings Calluk.finance.yahoo.com - February 22 at 1:24 AMSouthwest Virginia scientists are gene-editing pigs for human transplantscardinalnews.org - December 19 at 9:31 AMBest Stocks to Buy Right Nowbenzinga.com - November 22 at 6:57 PMMiromatrix Holder Says It Omitted United Therapeutics Deal Infonews.bloomberglaw.com - November 16 at 7:25 PMMiromatrix Medical GAAP EPS of -$0.24, revenue of $11.17Mmsn.com - November 15 at 1:53 PMMiromatrix Reports Third Quarter 2023 Resultsfinance.yahoo.com - November 14 at 8:27 PMMiromatrix Medical climbs 225% following $140m United Therapeutics bidproactiveinvestors.com - October 31 at 10:31 PMUnited Therapeutics agrees to buy Miromatrix Medicalmsn.com - October 31 at 10:31 PMUnited Therapeutics looks to hog bioengineered organ R&D with $91M Miromatrix buyfiercebiotech.com - October 31 at 12:30 PMMiromatrix Medical Shares Triple After United Therapeutics Offermarketwatch.com - October 31 at 12:30 PMUnited Therapeutics buying Miromatrix for up to $140Mbioworld.com - October 30 at 8:55 PMEden Prairie biotech company Miromatrix Medical sells for $91Mstartribune.com - October 30 at 10:48 AMUnited Therapeutics to buy Miromatrix Medical for $3.25 per sharemsn.com - October 30 at 10:48 AMWhy Is Miromatrix Medical (MIRO) Stock Up 235% Today?investorplace.com - October 30 at 9:13 AMMiromatrix to Present at the 2023 ISODP Organ Donation Congressfinance.yahoo.com - October 11 at 7:34 PMMiromatrix CEO Jeff Ross to Present at the 2023 Cell & Gene Meeting on the Mesafinance.yahoo.com - October 5 at 6:16 PMSeveral Insiders Invested In Miromatrix Medical Flagging Positive Newsfinance.yahoo.com - September 10 at 5:39 PMMiromatrix Announces Participation in the ARM Tissue Engineering and Therapeutics Workshopfinance.yahoo.com - September 5 at 4:52 PMMiromatrix Medical Inc. (NASDAQ:MIRO) Q2 2023 Earnings Call Transcriptfinance.yahoo.com - August 21 at 5:29 PMMiromatrix Medical Inc.: Miromatrix Reports Second Quarter 2023 Results and Provides Corporate Updatefinanznachrichten.de - August 15 at 4:21 PMMiromatrix Medical GAAP EPS of -$0.24msn.com - August 15 at 4:21 PMCraig-Hallum Keeps Their Buy Rating on Miromatrix Medical (MIRO)markets.businessinsider.com - August 15 at 4:21 PMQ2 2023 Miromatrix Medical Inc Earnings Callfinance.yahoo.com - August 15 at 9:47 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsERYTECH PharmaNASDAQ:ERYPERYTECH Pharma S.A., a biopharmaceutical company, focus on development of red blood cell-based therapeutics for cancer and orphan diseases in France and the United States. It develops eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing erymethionase, a preclinical product candidate that consists of methionine-?-lyase in red blood cells to target the amino acid metabolism of cancer cells and induce tumor starvation. ERYTECH Pharma S.A. was incorporated in 2004 and is headquartered in Lyon, France.Evaxion Biotech A/SNASDAQ:EVAXEvaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy that is in Phase 1/2a trial for adjuvant melanoma; and EVX-03, a DNA-based immunotherapy for the treatment of various cancers. Its programs also include EVX-B1, EVX-B2, and EVX-V1, which are vaccines that are in pre-clinical stage for the treatment of bacterial and viral diseases. Evaxion Biotech A/S was incorporated in 2008 and is based in Horsholm, Denmark.GenfitNASDAQ:GNFTGenfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France.Jasper TherapeuticsNASDAQ:JSPRJasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. It focuses on the development and commercialization of therapeutic agents for diseases, such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndrome, and novel conditioning regimens for stem cell transplantation and ex-vivo gene therapy, a technique in which genetic manipulation of cells is performed outside of the body prior to transplantation. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It is also developing engineered hematopoietic stem cells product candidates to overcome key limitations of allogeneic and autologous gene-edited stem cell grafts. The company is headquartered in Redwood City, California.Miromatrix MedicalNASDAQ:MIROMiromatrix Medical Inc., a life sciences company, develops a novel technology for bioengineering fully transplantable organs. The company's proprietary technology is a platform that uses a two-step method of decellularization and recellularization designed to remove the porcine cells from the organs obtained from pigs and replace them with unmodified human cells. It has collaborations with Baxter, CareDx, The Mayo Clinic, Mount Sinai Hospital, and The Texas Heart Institute. The company was formerly known as TayTech, Inc. Miromatrix Medical Inc. was incorporated in 2009 and is headquartered in Eden Prairie, Minnesota. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.